FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- Resource Type
- Article
- Authors
- Mehling, M; Brinkmann, V; Antel, J; Bar-Or, A; Goebels, N; Vedrine, C; Kristofic, C; Kuhle, J; Lindberg, R L.P.; Kappos, L
- Source
- Neurology (Ovid); October 2008, Vol. 71 Issue: 16 p1261-1267, 7p
- Subject
- Language
- ISSN
- 00283878; 1526632X
The oral immunomodulator FTY720 has shown efficacy in patients with relapsing multiple sclerosis (MS). FTY720 functionally antagonizes sphingosine 1-phosphate receptor-1 (S1P1) on T cells and consequently inhibits S1P/S1P1-dependent lymphocyte egress from secondary lymphoid organs. Little is known about the phenotype and function of T cells remaining in peripheral blood during long-term FTY720 treatment.